21Shares has filed an amended S-1/A registration statement for its proposed Injective ETF, with plans to list the product on Nasdaq under the ticker TINJ. The fund is designed to track the performance of the INJ token by using the FTSE Injective Index as its benchmark. The filing also says the fund may stake part of its INJ holdings when appropriate in order to earn staking rewards. The amendment relates to the initial application submitted in October 2025. The ETF has not been approved for listing at this stage, and its custody arrangement has yet to be finalized. The update was cited by Odaily, which referenced Crypto Briefing.

21Shares has filed an amended S-1/A registration statement with the U.S. Securities and Exchange Commission for its Injective ETF, according to Crypto Briefing. The filing updates the original application submitted in October 2025. If approved, the fund would trade on Nasdaq under the ticker TINJ and passively track the performance of the INJ token through the FTSE Injective Index. The filing also says the ETF may stake a portion of its holdings at its discretion to enhance yield. 21Shares has already launched an Injective staking ETP in Europe, and the new filing represents an expansion effort into the U.S. market.